Roche Says Illumina Takeover Would Hasten Sequencing’s Path To Diagnostics
This article was originally published in The Gray Sheet
With $5.7 billion hostile takeover attempt for next-generation gene sequencing powerhouse Illumina, Roche says it is uniquely situated to push sequencing into the routine clinical diagnostics space. But Illumina is resisting, which could push up the price and draw out the process.
You may also be interested in...
The acquisition gives Roche a big data platform for the centralized management and processing of next generation sequencing data.
More DME competitive bidding planned. AdvaMed outlines strategic plan. Roche ends Illumina bid, for now.
Boston Scientific touts stent wins. Biomet settles foreign bribery charges. Roche ups Illumina bid. Derma Sciences acquires MedEfficiency.